TELIX PHARMACEUTICALS LIMITED news, videos and press releases
For more news please use our advanced search feature.
TELIX PHARMACEUTICALS LIMITED - More news...
TELIX PHARMACEUTICALS LIMITED - More news...
- NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
- Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
- Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete
- Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
- Telix ADSs Commence Trading on Nasdaq
- Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
- Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology
- Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
- Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals
- Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®
- FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
- Telix Spins Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals
- Telix Files Form 20-F Registration Statement for Nasdaq ADS
- Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
- Telix Q3 2024 Business Update – Quarterly Revenue Exceeds AU$200M
- Health Canada Approves Label Expansion for Telix’s Illuccix® to Include Patient Selection for PSMA-Targeted Therapy
- First Patient Dosed in Phase II ‘CA-NINE’ Trial of TLX250-CDx for Detection of Recurrent Kidney Cancer After Surgery
- Telix to Acquire RLS to Expand North American Manufacturing and Distribution Platform
- Telix Announces Cardinal Health as U.S. Commercial Distributor for Zircaix®
- ‘Highly Accurate’: Telix’s Phase III ZIRCON Trial for Kidney Cancer Imaging Published in The Lancet Oncology
- IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
- Telix Submits NDA for TLX101-CDx (Pixclara™) Brain Cancer Imaging Agent
- Telix Announces Reorganisation to Deliver on Strategic Priorities
- Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
- Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities
- Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
- Telix Successfully Prices A$650 Million Convertible Bonds
- Telix Successfully Prices A$650 Million Convertible Bonds
- FDA Accepts Telix NDA for New Prostate Cancer Imaging Agent
- Telix Announces A$600 Million Convertible Bonds Offering
